Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026)

Zura Bio provided an updated corporate presentation highlighting tibulizumab Phase 2 timelines and $225.6M cash on hand.

Key Highlights:

• Furnished updated corporate presentation (Exhibit 99.1) under Regulation FD for investor conferences and meetings.
• Topline readout expected Q4 2026 for hidradenitis suppurativa Phase 2 (TibuSHIELD) and 1H 2027 for systemic sclerosis Phase 2 (TibuSURE).
• Reported ~$225.6M cash and cash equivalents as of March 31, 2026 and noted a February 2026 public offering to fund operations through at least end of 2028.
• Tibulizumab is described as the first-in-class bispecific targeting IL-17 and BAFF with Phase 1/1b data supporting Phase 2 advancement (78 participants dosed).
• Company plans to initiate a Phase 2 in a third immune-mediated indication by year-end 2026, subject to clinical validation.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.